The FDA in 2017 ripped Indian drugmaker Lupin in a warning letter for not learning from past mistakes. In a new visit to one of the two plants cited in that letter, the FDA has again found issues.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results